Business

CareDx Update Regarding Raymond James & Associates’ Conference

BRISBANE, Calif.--(BUSINESS WIRE)-- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of

articleCaredx, Inc.March 6, 20235/company/caredx-inc/news/caredx-update-regarding-raymond-james-associates-conference-2023-03-06
CareDx Update Regarding Raymond James & Associates’ Conference

About this update from Caredx, Inc.

[{"type":"text","content":" BRISBANE, Calif.--(BUSINESS WIRE)--\nCareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the Company has determined not to participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference scheduled for later today in light of scheduling conflicts. The company looks forward to providing its next corporate update in the near term.\n\nAbout CareDx – The Transplant Company\n\nCareDx, Inc., headquartered in Brisbane, California, is a leading precision medicine solutions company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230306005824/en/\n\nCareDx, Inc.\nInvestor Relations\nGreg Chodaczek\[email protected]\n\nSource: CareDx, Inc.","length":2806,"tagName":"div"}]

More updates from Caredx, Inc.